Explore the vast range of titles available.

Rheumatoid arthritis (RA) is a chronic autoimmune condition characterized by joint pain, fatigue, and reduced quality of life. Although pharmacological interventions, such as non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs), address physical symptoms, the psychological and emotional challenges associated with RA are frequently neglected. Social media platforms, particularly Reddit, have emerged as significant venue for patients to share experiences and seek support, a trend that has intensified during the COVID-19 pandemic. This study examined six years (2018–2024) of discussions from the r/rheumatoid and r/rheumatoidarthritis subreddits, encompassing 22,537 posts and 276,209 comments. Natural language processing (NLP) techniques were implemented to analyze sentiment, emotions, discussion topics, drug mentions, and hyperlink-sharing patterns across three phases: pre-COVID, during COVID, and post-COVID. The analysis indicated that comments were predominantly positive, whereas posts exhibited increased negativity following the onset of COVID-19. Fear and sadness were prevalent in posts, while comments frequently conveyed joy, underscoring the community’s supportive nature. Topic modeling identified recurring discussions concerning treatment efficacy, mental health, and pandemic-related disruptions. Methotrexate emerged as the most frequently mentioned medication, with notable emotional variation during the pandemic. Hyperlink patterns suggested an increasing reliance on medical and academic sources, reflecting patients’ need for reliable information. These findings illustrate how online communities capture evolving patient experiences and unmet needs. Insights from such discussions can inform healthcare providers, policymakers, and public health communicators in developing patient-centered strategies that address both the emotional and informational dimensions of RA care.

Cystic Fibrosis (CF) is a hereditary condition and can cause permanent respiration problems leading to degraded life quality. The most common variation leading to CF is the F508del variation. CF can cause damage to not just the lungs but also digestive system, pancreas, and other organs. CF decreases the life expectancy of the individuals affected with the constant fear of lung complications. The current methods of treatment include using a combination of drugs to manage the symptoms. The combination of drugs has many side effects and causes damage to other organs like liver, heart or kidneys. In this study, we aim to find a drug that can relieve the symptoms of CF. We began by creating a dataset of potential drug molecules, which was subsequently refined by removing harmful compounds through an ADMET scan. All these compounds were then docked to the mutated Cystic Fibrosis Transmembrane Regulator (CFTR) protein. The compounds with the best docking affinity were Galicaftor and Bamocaftor. A currently approved drug, Ivacaftor was selected as control for the 200 ns Molecular Dynamics (MD) Simulation. The simulation revealed that the CFTR protein remained more stable and compact when complexed with Bamocaftor, when compared to Ivacaftor and Galicaftor. Moreover, the MMPBSA free energy calculations revealed that the free energy of the CFTR-bamocaftor complex is the lowest compared to the other complexes. Our findings reveal the action of bamocaftor on CFTR protein with p.Phe508del variation. However, the absence of in-vivo or in-vitro studies is a limitation, and further experimental validation is necessary to confirm its efficacy and safety.

Cystic Fibrosis (CF) is a hereditary condition and can cause permanent respiration problems leading to degraded life quality. The most common variation leading to CF is the F508del variation. CF can cause damage to not just the lungs but also digestive system, pancreas, and other organs. CF decreases the life expectancy of the individuals affected with the constant fear of lung complications. The current methods of treatment include using a combination of drugs to manage the symptoms. The combination of drugs has many side effects and causes damage to other organs like liver, heart or kidneys. In this study, we aim to find a drug that can relieve the symptoms of CF. We began by creating a dataset of potential drug molecules, which was subsequently refined by removing harmful compounds through an ADMET scan. All these compounds were then docked to the mutated Cystic Fibrosis Transmembrane Regulator (CFTR) protein. The compounds with the best docking affinity were Galicaftor and Bamocaftor. A currently approved drug, Ivacaftor was selected as control for the 200 ns Molecular Dynamics (MD) Simulation. The simulation revealed that the CFTR protein remained more stable and compact when complexed with Bamocaftor, when compared to Ivacaftor and Galicaftor. Moreover, the MMPBSA free energy calculations revealed that the free energy of the CFTR-bamocaftor complex is the lowest compared to the other complexes. Our findings reveal the action of bamocaftor on CFTR protein with p.Phe508del variation. However, the absence of in-vivo or in-vitro studies is a limitation, and further experimental validation is necessary to confirm its efficacy and safety.